2024-511187-81-00已完成3 期
A Phase 3 Multicenter, Randomized, Openlabel, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator’s Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation
Amgen Inc.21 个研究点 分布在 5 个国家目标入组 99 人开始时间: 2022年4月19日最近更新:
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 99
- 试验地点
- 21
- 主要终点
- PFS – defined as time from randomization until disease progression or death from any cause, whichever occurs first, for all subjects. Progression will be assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per Blinded Independent Central Review (BICR)
研究概览
简要总结
To compare progressionfree survival (PFS) in previously treated subjects with KRAS p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator’s choice (trifluridine and tipiracil or regorafenib), and sotorasib 960 mg QD and panitumumab vs investigator’s choice (trifluridine and tipiracil or regorafenib)
研究设计
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Subject has provided informed consent/assent prior to initiation of any study specific activities/procedures.
- •Fridericia's Correction Formula (QTcF) ≤ 470 msec
- •Ability to take oral medications and willing to record daily adherence to investigational product.
- •Age ≥ 18 years.
- •Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation as determined by prospective central testing, using the analytically validated Qiagen Therascreen KRAS RGQ polymerase chain reaction (PCR) kit in CRC as an investigational device demonstrating a KRAS p.G12C mutation is present. Local testing and documentation of KRAS p.G12C mutation should have been previously performed as part of standard of care.
- •Subjects will have received at least 1 prior line of therapy for metastatic disease. Subjects must have received and progressed or experienced disease recurrence on or after fluoropyrimidine, irinotecan, and oxaliplatin given for metastatic disease unless the subject, in the opinion of the investigator, is not a candidate for fluoropyrimidine, irinotecan, or oxaliplatin, in which case, the subject may be eligible after investigator discussion with Amgen medical monitor provided subject has received at least one prior line of therapy for metastatic disease and provided trifluridine and tipiracil or regorafenib is deemed the appropriate next line of therapy for the subject. Notes: Subjects with tumors known to be MSI-H must have received prior checkpoint inhibitor therapy if available in the region unless there is a medical contraindication, in which case, the subject may be eligible after investigator discussion with Amgen medical monitor. Subjects with tumors known to have BRAF V600E mutation must have received prior treatment with encorafenib and cetuximab if available for this indication in the country or region unless there is a medical contraindication in the opinion of the investigator, in which case the subject may be eligible for the trial after investigator discussion with and approval of the Amgen medical monitor. Adjuvant therapy will count as a line of therapy for metastatic disease if the subject progressed on or within six months of completion of adjuvant therapy administration. Maintenance therapy is not considered as a separate regimen of therapy. Adjuvant therapy given after resection of metastatic disease counts as a line of therapy for metastatic disease. Perioperative chemotherapy with or without chemoradiation in the metastatic setting will count as one line of therapy for metastatic disease if that was part of a multidisciplinary treatment plan for surgery.
- •Subjects must be willing to provide archived tumor tissue samples (formalin-fixed paraffin-embedded [FFPE] sample collected within 5 years) or agree to undergo a pretreatment tumor biopsy (excisional or core biopsy) prior to enrollment.
- •Measurable disease per RECIST 1.1 criteria. Lesions previously radiated are not considered measurable unless they have progressed after radiation.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2
- •Life expectancy of > 3 months, in the opinion of the investigator
- •Adequate hematologic and end-organ function, defined as the following within 2 weeks prior to cycle 1 day 1: Absolute neutrophil count (ANC) ≥ 1.5 x 109 /L (without granulocyte colony-stimulating factor support within 2 weeks of laboratory test used to determine eligibility) Hemoglobin ≥ 9.0 g/dL (without transfusion within 2 weeks of laboratory test used to determine eligibility) Platelet count ≥ 100 x 109 /L (without transfusion within 2 weeks of laboratory test used to determine eligibility) Aspartate aminotransferase (AST) and ALT ≤ 2.5 times the upper limit of normal (ULN) Serum bilirubin ≤ 1.0 x ULN. For subjects with Gilbert’s disease, total bilirubin or direct bilirubin needs to be ≤ 1.0 x ULN International normalized ratio (INR) and activated partial thromboplastin time (or partial thromboplastin time) ≤ 1.5 x ULN. Prothrombin time (PT) ≤ 1.5 x ULN may be used instead of INR for sites whose labs do not report INR Estimated glomerular filtration rate based on Modification of Diet in Renal Disease (MDRD) calculation ≥ 30 mL/min/1.73 m2
排除标准
- •Active brain metastases. Subjects who have had brain metastases resected or have received radiation therapy ending at least 4 weeks prior to study day 1 are eligible
- •Known history of human immunodeficiency virus infection
- •Exclusion of hepatitis infection based on the following results and/or criteria: a)Positive hepatitis B surface antigen b)Negative HepBsAg with a positive for hepatitis B core antibody c)Positive Hepatitis C virus antibody: Hepatitis C virus RNA by polymerase chain reaction is necessary. Detectable Hepatitis C virus RNA renders the subject ineligible. If above antibody/antigen testing is not able to be obtained, positive hepatitis B or C viral load
- •Subjects have received both trifluridine and tipiracil and regorafenib in the past
- •Unresolved toxicities from prior anti-tumor therapy
- •Previous treatment with a KRAS G12C inhibitor
- •Prior treatment with trifluridine and tipiracil in those subjects where investigator's choice would be trifluridine and tipiracil
- •Prior treatment with regorafenib in those subjects where investigator's choice would be regorafenib
- •Therapeutic or palliative radiation therapy within 2 weeks of study day 1
- •Anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, retinoid therapy, hormonal therapy [except for subjects with history of completely resected breast cancer with no active disease for over 3 years on long term adjuvant endocrine therapy], or investigational agent) within 4 weeks of study day 1; please note that bisphosphonates or anti-RANKL antibody therapy is allowed if needed for management of hypercalcemia or for prevention of skeletal events. Checkpoint inhibitor therapy within 6 weeks of study day 1 is also excluded
- •Required dose reduction of panitumumab in the past for toxicity
- •History or presence of hematological malignancies unless curatively treated with no evidence of disease 2 years
- •Use of warfarin. Other anticoagulation may be allowed
- •Use of known cytochrome P450 (CYP) 3A4 sensitive substrates and P-glycoprotein (P-gp) substrates (with a narrow therapeutic window), within 14 days or 5 half-lives of the drug or its major active metabolite, whichever is longer, prior to study day 1
- •Use of strong inducers of CYP3A4 within 14 days or 5 half-lives prior to study day 1
- •Where Investigator's choice is regorafenib: use of strong inhibitors of CYP3A4 (including herbal supplements such as Goldenseal) within 14 days or 5 half-lives (whichever is longer) or grapefruit juice or grapefruit containing products within 7 days prior to study day 1
- •Therapeutic oral or IV antibiotics within 2 weeks prior to randomization
- •History of other malignancy within the past 3 years, with exceptions specified in the protocol
- •Leptomeningeal disease
- •Significant GI disorder that results in significant malabsorption, requirement for IV alimentation, or inability to take oral medication
- •History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis
- •Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 6 months prior to randomization, unstable arrhythmias or unstable angina
- •Significant uncontrolled concomitant disease that could affect compliance with protocol procedures or interpretation of results or that pose a risk to subject safety
- •Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures at a frequency greater than monthly.
研究组 & 干预措施
SOTORASIB
Test
干预措施: SOTORASIB (Drug)
Vectibix 20 mg/ml concentrate for solution for infusion, Vectibix 20 mg/ml concentrate for solution for infusion
Test
干预措施: Vectibix 20 mg/ml concentrate for solution for infusion (Drug)
Stivarga 40 mg film-coated tablets, Stivarga 40 mg film-coated tablets
Comparator
干预措施: Stivarga 40 mg film-coated tablets (Drug)
Lonsurf 20 mg/8.19 mg film-coated tablets, Lonsurf 15 mg/6.14 mg film-coated tablets
Comparator
干预措施: Lonsurf 20 mg/8.19 mg film-coated tablets (Drug)
Lonsurf 20 mg/8.19 mg film-coated tablets, Lonsurf 15 mg/6.14 mg film-coated tablets
Comparator
干预措施: Lonsurf 15 mg/6.14 mg film-coated tablets (Drug)
结局指标
主要结局
PFS – defined as time from randomization until disease progression or death from any cause, whichever occurs first, for all subjects. Progression will be assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per Blinded Independent Central Review (BICR)
PFS – defined as time from randomization until disease progression or death from any cause, whichever occurs first, for all subjects. Progression will be assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per Blinded Independent Central Review (BICR)
次要结局
- Pharmacokinetic (PK) parameters of sotorasib and panitumumab including, but not limited to, maximum plasma concentration (Cmax), area under the plasma concentration-time curve (AUC)
- Overall survival - defined as time from randomization until death from any cause
- Objective response = complete response (CR) + partial response (PR), assessed per RECIST 1.1. Response will be assessed by BICR. CR and PR require confirmatory repeat assessment at least 4 weeks after the first detection of response
- Incidence and severity of treatmentemergent adverse events, changes in vital signs, and changes in clinical laboratory tests
- Change from baseline over time to week 8 Fatigue severity measured by item 3 on the brief faigure invetory
- Change from baseline over time to 8 weeks for the BFI, BPI and EORTC QLQ-C30. Summary scores and changes from baseline of VAS scores as measured by EuroQol-5D level 5. Summary scores on symptom bother on GP5 from FACT-G. Summary scores of Patient Global Impression of change at each timepoint.
- Duration of overall response - defined as time from first evidence of PR or CR to disease progression or death due to any cause, whichever occurs first. Progression will be based on BICR per RECIST 1.1
研究者
Medical Information
Scientific
Amgen Inc.
研究点 (21)
Loading locations...
相似试验
招募中
3 期
Phase 3 study of RMC-6236 in patients with previously treated metastatic PDAC2024-516063-89-00Revolution Medicines Inc.80
尚未招募
2 期
ENGIC 01 - COLOSOTO: A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) in first-line treatment of patients non-eligible for a doublet/triplet chemotherapy with advanced unresectable KRAS G12C mutated colorectal adenocarcinomacolorectal cancer2024-514030-20-00Fondation Franc.Cancerologie Digestive37
尚未招募
2 期
Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Advanced or Metastatic Solid Tumors With the KRASG12C MutationNCT07318649Suzhou Genhouse Bio Co., Ltd.120
招募中
3 期
A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.362025-522084-15-00IRCCS Istituto Nazionale Tumori Fondazione Pascale36
招募中
4 期
Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed on platinum-based chemotherapy2022-501606-35-01Immunogen Biopharma (Ireland) Limited, Immunogen Inc.110